SCHEMBL411769

SCHEMBL411769

Cc1ccnc(C)c1C(=O)Cl

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
CCR5 P51681 8/20 0.36
CCR1 P32246 1/20 0.35
CCR8 P51685 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NOS3 P29474 2/20 0.34
NOS2 P35228 2/20 0.34
P2RX7 Q99572 1/20 0.34
KCNH2 Q12809 1/20 0.34
SLC6A9 P48067 1/20 0.34
LIMK1 P53667 1/20 0.33
SIRT3 Q9NTG7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TYK2 P29597 1/20 0.33
CYP2A6 P11509 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3283632 0.98 ITGB1 (0.36) ITGB1ITGA4CCR5CCR1CCR8
SCHEMBL30674019 0.86 ALDH1A1 (0.48) ITGB1ITGA4CCR5ALDH1A1P2RX7
SCHEMBL26941587 0.86 ALDH1A1 (0.48) ITGB1ITGA4CCR5ALDH1A1P2RX7
SCHEMBL10561174 0.82 ALDH1A1 (0.39) CCR5CCR1CCR8ALDH1A1NOS3
SCHEMBL6628045 0.81 CSNK1A1 (0.38) ITGB1ITGA4CCR5CCR1CCR8
SCHEMBL31662998 0.81 CSNK1A1 (0.38) ITGB1ITGA4CCR5CCR1CCR8
SCHEMBL353204 0.81 KDM4E (0.40) ITGB1ITGA4CCR5CCR1CCR8
SCHEMBL1260587 0.80 ALDH1A1 (0.33) CCR5CCR1CCR8ALDH1A1NOS3
Hydrochloric Acid SCHEMBL4249059 0.79 KDM4E (0.39) ITGB1ITGA4CCR5CCR1CCR8
SCHEMBL9504653 0.79 KDM4E (0.39) ITGB1ITGA4CCR5CCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111454203-A Synthetic method of 2-chloro-N, N-dimethylnicotinamide 山东京博生物科技有限公司 2020-07-28 CN disclosed
US-20120065397-A1 PREPARATION OF KETONE AMIDES Scherimg Corporation (US) 2012-03-15 US disclosed
US-20120065397-A1 PREPARATION OF KETONE AMIDES Scherimg Corporation (US) 2012-03-15 US disclosed
US-7759487-B2 Preparation of ketone amides SCHERING CORPORATION (US) 2010-07-20 US disclosed
US-7759487-B2 Preparation of ketone amides SCHERING CORPORATION (US) 2010-07-20 US disclosed
US-7714018-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
US-20100029939-A1 PREPARATION OF KETONE AMIDES SCHERING CORPORATION 2010-02-04 US disclosed
US-20100029939-A1 PREPARATION OF KETONE AMIDES SCHERING CORPORATION 2010-02-04 US disclosed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN disclosed
US-20070117859-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-05-24 US disclosed
EP-1761542-A2 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US disclosed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US disclosed
WO-2005121145-A2 OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029939-A1 PREPARATION OF KETONE AMIDES CCR5, CCR2, ACKR3 ITGB1 1838/4885ITGA4 1111/4885CCR5 1/4885
US-20060014767-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 ITGB1 1323/4885ITGA4 2337/4885CCR5 1/4885
US-20120065397-A1 PREPARATION OF KETONE AMIDES CCR5, CCR2, ACKR3 ITGB1 1838/4885ITGA4 1111/4885CCR5 1/4885
US-20070117859-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 ITGB1 1323/4885ITGA4 2337/4885CCR5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.